FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308396197> ?p ?o ?g. }

• W4308396197 abstract "<h3>Background</h3> Despite advances in therapy, the prognosis of hepatocellular carcinoma (HCC) remains poor. The introduction of biologic drugs, including immune check-point inhibitors, has revolutionized HCC treatment. However, only a portion of patients with HCC respond to immunotherapy and predicting response is an unmet need. In this preliminary study, we assessed the value of quantitative multiparametric MRI (mpMRI) for predicting HCC response to neoadjuvant immunotherapy. <h3>Methods</h3> In this prospective IRB-approved single-center study, we included 17 patients (M/F 14/3, mean age 65y) with resectable HCC who underwent mpMRI including T1 mapping, 3D MR elastography (MRE), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE)-MRI with a hepatobiliary contrast agent (gadoxetic acid, Eovist/Primovist, Bayer), at pre-treatment and after completion of anti PD-1 immunotherapy (cemiplimab) as part of a trial. All patients underwent surgical resection. HCC lesions were identified by an experienced radiologist and regions of interest were placed to measure tumor native and post-contrast T1 measured during hepatobiliary phase (T1-HBP), tumor stiffness (TS), apparent diffusion coefficient (ADC), and perfusion parameters. The reference standard was the histopathologic percentage of necrosis. Patients with significant tumor necrosis (STN ≥50%) were considered responders. MRI parameters were compared between responders and non-responders by Mann-Whitney U test, and their diagnostic performance to predict response to treatment was assessed by ROC analysis. <h3>Results</h3> 17 HCC lesions (6.4±4.9 cm, range 2.0-19.0 cm) were resected in 17 patients. At pre-treatment MRI, tumor native T1 and upslope from DCE-MRI were prolonged in responders compared to non-responders, and predicted response with good diagnostic performance (table 1; T1 AUC(CI)=0.82(0.58-0.99), upslope AUC(CI)=0.80(0.58-0.99). The other parameters had no value in predicting response to immunotherapy (AUC range 0.52-0.68). Tumor native T1 and T1-HBP increased with degree of tumor necrosis at resection (%). <h3>Conclusions</h3> Our results demonstrate the potential utility of native T1 and upslope measured with DCE-MRI for predicting HCC response to neoadjuvant immunotherapy. These findings require validation in an independent study. <h3>Acknowledgements</h3> Regeneron Pharmaceuticals, Inc. funded the study. We would like to thank our clinical coordinators, Jordan Cuevas and Jenna Korotkin for helping with patient consent and for maintaining the study database. Enamul H. Bhuiyan gratefully acknowledges Professor Steven Sourbron, The University of Sheffield for his generosity to provide updated PMI software. <h3>Trial Registration</h3> Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC clinicaltrials.gov identifier NCT03916627 <h3>Ethics Approval</h3> The study obtained continuing approval from the IRB at Mount Sinai through 01/19/2023, for Regeneron Pharmaceuticals, Inc. Protocol # R2810-ONC-1866/PI: Marron/BRANY File # 19-06-061-05. All participants signed informed consent." @default.
• W4308396197 created "2022-11-11" @default.
• W4308396197 creator A5001917298 @default.
• W4308396197 creator A5002724220 @default.
• W4308396197 creator A5006241604 @default.
• W4308396197 creator A5007545977 @default.
• W4308396197 creator A5008619587 @default.
• W4308396197 creator A5012600570 @default.
• W4308396197 creator A5022761217 @default.
• W4308396197 creator A5029868837 @default.
• W4308396197 creator A5052682352 @default.
• W4308396197 creator A5054039682 @default.
• W4308396197 creator A5057343975 @default.
• W4308396197 creator A5070354041 @default.
• W4308396197 creator A5078046623 @default.
• W4308396197 creator A5082093033 @default.
• W4308396197 creator A5085214636 @default.
• W4308396197 creator A5087395019 @default.
• W4308396197 date "2022-11-01" @default.
• W4308396197 modified "2023-10-12" @default.
• W4308396197 title "688 Prediction of HCC response to neoadjuvant immunotherapy using multiparametric magnetic resonance imaging: a preliminary study" @default.
• W4308396197 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0688" @default.
• W4308396197 hasPublicationYear "2022" @default.
• W4308396197 type Work @default.
• W4308396197 citedByCount "0" @default.
• W4308396197 crossrefType "proceedings-article" @default.
• W4308396197 hasAuthorship W4308396197A5001917298 @default.
• W4308396197 hasAuthorship W4308396197A5002724220 @default.
• W4308396197 hasAuthorship W4308396197A5006241604 @default.
• W4308396197 hasAuthorship W4308396197A5007545977 @default.
• W4308396197 hasAuthorship W4308396197A5008619587 @default.
• W4308396197 hasAuthorship W4308396197A5012600570 @default.
• W4308396197 hasAuthorship W4308396197A5022761217 @default.
• W4308396197 hasAuthorship W4308396197A5029868837 @default.
• W4308396197 hasAuthorship W4308396197A5052682352 @default.
• W4308396197 hasAuthorship W4308396197A5054039682 @default.
• W4308396197 hasAuthorship W4308396197A5057343975 @default.
• W4308396197 hasAuthorship W4308396197A5070354041 @default.
• W4308396197 hasAuthorship W4308396197A5078046623 @default.
• W4308396197 hasAuthorship W4308396197A5082093033 @default.
• W4308396197 hasAuthorship W4308396197A5085214636 @default.
• W4308396197 hasAuthorship W4308396197A5087395019 @default.
• W4308396197 hasBestOaLocation W43083961971 @default.
• W4308396197 hasConcept C121608353 @default.
• W4308396197 hasConcept C126322002 @default.
• W4308396197 hasConcept C126838900 @default.
• W4308396197 hasConcept C143409427 @default.
• W4308396197 hasConcept C143753070 @default.
• W4308396197 hasConcept C2777690781 @default.
• W4308396197 hasConcept C2777701055 @default.
• W4308396197 hasConcept C2778019345 @default.
• W4308396197 hasConcept C2778292576 @default.
• W4308396197 hasConcept C2779124084 @default.
• W4308396197 hasConcept C2989005 @default.
• W4308396197 hasConcept C530470458 @default.
• W4308396197 hasConcept C58471807 @default.
• W4308396197 hasConcept C70816921 @default.
• W4308396197 hasConcept C71924100 @default.
• W4308396197 hasConceptScore W4308396197C121608353 @default.
• W4308396197 hasConceptScore W4308396197C126322002 @default.
• W4308396197 hasConceptScore W4308396197C126838900 @default.
• W4308396197 hasConceptScore W4308396197C143409427 @default.
• W4308396197 hasConceptScore W4308396197C143753070 @default.
• W4308396197 hasConceptScore W4308396197C2777690781 @default.
• W4308396197 hasConceptScore W4308396197C2777701055 @default.
• W4308396197 hasConceptScore W4308396197C2778019345 @default.
• W4308396197 hasConceptScore W4308396197C2778292576 @default.
• W4308396197 hasConceptScore W4308396197C2779124084 @default.
• W4308396197 hasConceptScore W4308396197C2989005 @default.
• W4308396197 hasConceptScore W4308396197C530470458 @default.
• W4308396197 hasConceptScore W4308396197C58471807 @default.
• W4308396197 hasConceptScore W4308396197C70816921 @default.
• W4308396197 hasConceptScore W4308396197C71924100 @default.
• W4308396197 hasLocation W43083961971 @default.
• W4308396197 hasOpenAccess W4308396197 @default.
• W4308396197 hasPrimaryLocation W43083961971 @default.
• W4308396197 hasRelatedWork W2061362175 @default.
• W4308396197 hasRelatedWork W2321533072 @default.
• W4308396197 hasRelatedWork W2324778341 @default.
• W4308396197 hasRelatedWork W2385067255 @default.
• W4308396197 hasRelatedWork W2565527428 @default.
• W4308396197 hasRelatedWork W2977910349 @default.
• W4308396197 hasRelatedWork W3028797934 @default.
• W4308396197 hasRelatedWork W3144237865 @default.
• W4308396197 hasRelatedWork W4281921891 @default.
• W4308396197 hasRelatedWork W4206894848 @default.
• W4308396197 isParatext "false" @default.
• W4308396197 isRetracted "false" @default.
• W4308396197 workType "article" @default.